China Supplier of High Quality Anti-Fibrosis Drug Pirfenidone for Health Treatment

Quick Detail for Pirfenidone
CAS: 53179-13-8
Solubility: DMSO: 10 mg/mL, soluble
Appearance: White crystal powder
Melting Point: 102--109
Loss on drying: <1.0%
Known single impurity: <1.0%
Unknown single impurity: <0.5%
Total impurity: <2.0%
Assay(as dried): 99%min

Overview

Pirfenidone (PFD) is a novel kind ketones which has a broad-spectrum anti-fibrotic effect, being able to prevent and reverse the formation of fibrosis and scar. It into into market in Shionogi, Japan in 2008 and has been approved by the US drug and Drug Administration. It is the first drug which has gone through phase III clinical trials (including repeating, randomized, and placebo-control) which has its effectiveness in treatment idiopathic pulmonary fibrosis (IPF); moreover, the drug has relative good efficacy in treatment some fibrotic diseases such as renal interstitial fibrosis and liver fibrosis. accident, it is also extensive applied in the phase II clinical study in kidney disease (focal segmental glomerulosclerosis), hypertrophic cardiomyopathy, adult type I neurofibromatosis, of neurofibromatosis and plexiform neurofibromas, diabetes union with kidney disease.


Clinical application

1. Idiopathic pulmonary fibrosis degeneration
Idio-pathic pulmonary fibrosis (idio-pathic pulmonary fibrosis, IPF) is a cause of unknown, poor prognosis, high mortality of chronic inflammatory interstitial lung disease, and PFD is an anti-inflammatory, anti-fibrosis agents, Can be used for the treatment of IPF.

2. liver fibrosis

3. Renal fibrosis

4. Multiple sclerosis
Multiple sclerosis (multiple sclerosis, MS) is associated with central nervous system and immune-related inflammation and demyelinating disease. The associated immune factors are the activation of stellate cells, glial cells, endothelial cells and lymphocytes, whereas PFD has the ability to inhibit cell activation.

5. Myocardial fibrosis
Cardiovascular diseases such as hypertension, cardiomyopathy and atrial fibrillation can lead to fibrosis of the myocardium, and thus the deterioration of the disease or the development of PFD treatment of sexual levator dystrophy caused by cardiomyopathy, can inhibit myocardial fibrosis, improve Heart function. PFD reduces myocardial remodeling and atrial fibrillation by inhibiting fibrosis.

6. Tumor disease: neurofibroma, uterine leiomyoma, malignant glioma.

7. Prevention of fibrosis after organ transplantation

8. Rheumatoid arthritis



Our Advantages

The comments from our clients